Status:
COMPLETED
Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer
Lead Sponsor:
Hospital Erasto Gaertner
Conditions:
Cachexia; Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Compare the use of nandrolone associated with corticosteroid for the treatment of cancer-induced malnutrition to treatment with corticosteroids alone in patients with tumors in the high gastro-intesti...
Detailed Description
* Compare muscle mass values obtained before and after the use of anabolic steroids upon assessment by bioelectrical impedance analysis (BIA). * Compare the anabolic effect on quality of life (QLo) of...
Eligibility Criteria
Inclusion
- Cancer patients above 18 years old.
- Patients with tumors in the high gastro-intestinal, hepatobiliary and pancreatic tracts in palliation.
- Patients able to undergo BIA.
- Malnourished patients as per the subjective global assessment produced by the patient (ASG-PPP) and whose score is greater than nine.
- Patients who agree to participate in the study.
Exclusion
- Patients with malignant tumors of other metachronous or synchronous location except nonmelanoma skin tumor
- Patients with chronic renal failure.
- Patients on diuretics, recent or chronic.
- Patients on appetite stimulants and anabolic agents.
- Patients using pacemakers, which can interfere with the results of BIA
Key Trial Info
Start Date :
February 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03263520
Start Date
February 1 2016
End Date
October 31 2017
Last Update
February 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil, 81520060